Kinfo
GRI Bio Inc. logo

GRI Bio Inc.

GRINASDAQHealthcare·US · USD
$1.54
-0.03 (-1.91%)
Prices as of October 13, 2026 · live

Price

Key statistics

Valuation
Market cap3.43M USD
Enterprise value-7.47M USD
Trailing P/E0.04
Forward P/E-0.79
PEG ratio-0.00
Price / sales0.00
Price / book0.33
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-70.93%
Return on equity-142.02%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-9.68M USD
Net income-9.66M USD
Diluted EPS-$16.40
Rev. growth (YoY)0.00%
Balance sheet
Total cash10.95M USD
Total debt44.00K USD
Debt / equity0.43
Current ratio10.30
Book value / share$4.70
Cash flow (TTM)
Operating cash flow-10.41M USD
Levered free cash flow-6.59M USD
Shares & price
Shares outstanding2.19M
Float2.19M
Held by institutions4.28%
Beta-0.61
50-day MA$1.88
200-day MA$2.66
52-week high$64.12
52-week low$1.36
Dividends
Forward rate
$2.04
Yield
132.73%
Payout ratio
0.00%
Frequency
Quarterly
Recent payments
  • 2019-12-19$23,715.51
Earnings (EPS)
DateEst.ActualSurprise2026-08-14-1.19-0.91+23.53%2026-05-13-3.74-1.61+56.95%2026-01-30-29.26-116.61−298.53%2025-11-14-31.08-35.84−15.32%2025-08-14-36.68-36.68+0.00%
About GRI Bio Inc.

GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. GRI Bio’s current pipeline centers on Natural Killer T cell modulators designed to help regulate immune responses that contribute to serious disease progression. Its lead program, GRI-0621, is an oral candidate being developed for severe fibrotic lung diseases, including idiopathic pulmonary fibrosis. The company is also advancing GRI-0803 for autoimmune disorders, alongside additional early-stage programs and a proprietary library of compounds that support its research pipeline. Based in La Jolla, California, GRI Bio Inc. operates in the biotechnology sector and concentrates on translating immune-system biology into drug candidates for unmet medical needs in specialty disease areas.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. W. Marc Hertz Ph.D.
Employees
3
Headquarters
La Jolla, CA, United States

Frequently asked questions about GRI Bio Inc.